化湿润燥汤治疗原发性干燥综合征的双盲随机对照试验及RNA修饰分析
本研究通过双盲随机安慰剂对照试验评估化湿润燥汤治疗原发性干燥综合征的疗效与安全性,并探索其表观遗传机制。结果显示化湿润燥汤改善外分泌腺功能及主观症状,降低疾病活动度,提高生活质量,并可能通过HNRNPA2B1调控m6A和m5C RNA修饰水平。
要点
- 化湿润燥汤可增加原发性干燥综合征患者唾液和泪液分泌。
- 化湿润燥汤改善口干、眼干、干燥感及肢体疼痛等主观症状。
- 化湿润燥汤可能通过HNRNPA2B1改变m6A和m5C RNA修饰水平。
核心结论
- 化湿润燥汤可能是原发性干燥综合征的有前景治疗,尤其对腺体损伤有效。
- 其疗效可能通过改变HNRNPA2B1基因、调整m6A和m5C水平实现。
研究设计与样本
- 双盲、随机、安慰剂对照临床试验。
- 纳入原发性干燥综合征患者,记录临床评分、疾病活动度、外分泌腺功能、血清学指标及SF-36评分。
- 采集患者和健康志愿者外周血样本测定RNA甲基化水平及调控因子表达。
主要发现
- 化湿润燥汤增加唾液分泌(P=0.049)和泪液分泌(P=0.005)。
- 改善口干(P<0.001)、眼干(P=0.004)、干燥(P=0.001)和肢体疼痛(P=0.008)视觉模拟评分。
- 降低ESSPRI(P=0.001)和ClinESSDAI(P=0.038),提高生活质量。
- 患者m6A水平升高、m5C水平降低,HNRNPA2B1为潜在关键表观遗传调控因子。
临床怎么用
- 可考虑用于原发性干燥综合征患者,尤其关注腺体损伤改善。
- 治疗期间可监测唾液流率、Schirmer试验及主观症状评分变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Huashi Runzao decoction (HRD), a Chinese herbal formula, has been used in clinical practice for patients with primary Sjögren disease (pSD) for years. However, the benefits of HRD for pSD have not been evaluated, and HRD epigenetic mechanism of action remains unexplored. OBJECTIVES: We conducted a double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of HRD in patients with pSD and to explore its epigenetic mechanism of action. METHODS: The clinical scores (including oral dryness, dry eye, dryness, fatigue, and limb pain visual analogue scales scores and the ESSPRI) of pSD patients were recorded at baseline and every 4 weeks thereafter. The disease activity scores (including the ESSDAI and ClinESSDAI), exocrine gland function variables (including the result of Schirmer's test and salivary flow rate), serological indices (ESR, CRP, IgG, IgA, and IgM) and short-form-36 health survey (SF-36) score were evaluated at baseline and 12 weeks later. Peripheral blood samples were collected from patients and healthy volunteers to determine RNA methylation (m6A and m5C) levels and analyse regulatory factor expression. RESULTS: HRD improved exocrine gland function in pSD patients and increased saliva (P = 0.049) and tear (P = 0.005) secretion. It also improved patients' perceptions of subjective symptoms, including oral dryness (P < 0.001), dry eye (P = 0.004), dryness (P = 0.001), and limb pain (P = 0.008) and yielded greater ESSPRIs (P = 0.001), reduced patients' disease activity according to the ClinESSDAI (P = 0.038) and improved their quality of life. Moreover, HRD increased m6A levels and decreased m5C levels in pSD patients, and HNRNPA2B1 was identified as a potential key epigenetic regulator. CONCLUSION: HRD, a Chinese herbal medicine, may be a promising treatment for pSD, especially for glandular damage. The therapeutic effects of this decoction may be achieved by alteration of the HNRNPA2B1 gene, altering m6A and m5C levels in pSD patients.
引用
- Huang Z, Deng T, Zhang X, et al. Huashi Runzao decoction for primary Sjögren disease: a double-blind, randomized controlled trial combined with m6A and m5C RNA modification analysis. Front Pharmacol. 2025. PMID: 41244818. doi:10.3389/fphar.2025.1618649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。